(MedPage Today) -- ATLANTA -- An investigational quadruple receptor agonist led to a substantial reduction in total body weight with minimal gastrointestinal adverse effects and no observed muscle loss, according to a phase II trial. The oral... Read more
Medpagetoday - Nov 09
And more biotech news stories brought to you by The Readout. Read more
Stat - Oct 14
Much excitement has built in recent years on the new class of incretin drugs that include glucagon-like-peptide-1 inhibitor (single agonists such as semaglutide) and also dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonists (dual agonists such tirzepatide). Read more
Medical News - Sep 22
Even the main character can be unlikeable.View Entire Post › Read more
Buzzfeed - Sep 21
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.Keybanc analyst Aleksey Yefremov initiated coverage on Avient Corporation (NYSE:AVNT) with an O... Read more
Benzinga - Sep 17
